Baxter Receives EMEA Positive Opinion For CELVAPAN, The First Cell Culture-Based Pandemic Flu Vaccine
Baxter International Inc. (NYSE: BAX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion for the marketing authorization of CELVAPAN, the first cell culture-based H5N1 (avian flu) pandemic vaccine, in the European Union.
More: continued here
Filed under: Flu / SARS on January 3rd, 2009